12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

AstraZeneca, Bristol-Myers, Ono Pharmaceutical sales and marketing update

Bristol-Myers Squibb and AstraZeneca are pulling Type II diabetes drug Forxiga dapagliflozin off the market in Germany after failing to agree on a price with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). The partners said they may reexamine the move after a price for Forxiga is determined through independent arbitration, which is expected in 1Q14. In June,...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >